Bacterium Dermatology Generic Drugs Trials 
pharmaphorum
DECEMBER 1, 2021
The French group said that ORI-001, a vaccine based on recombinant proteins from the Cutibacterium acnes (formerly Propionibacterium acnes ) bacterium that is often found in acne lesions, could be the first ever vaccine for the condition. C acnes is implicated in moderate to severe acne, which is difficult to treat.
XTalks
AUGUST 2, 2023
This is largely due to failed trials as a prophylaxis resulting in the European Committee for Medical Products (CHMP) recommending against the approval of Lagevrio. Other drugs also contributed to Merck’s revenue growth. Toujeo generated Sanofi €1.12 Lagevrio made up a large proportion of Merck’s revenue increase with $5.68
Expert insights. Personalized for you.
105 
Let's personalize your content